Sign in

    David Rosa

    Chief Executive Officer, President, and Director at NeuroOne Medical Technologies Corp
    Board
    Since July 2017
    Age
    60 years
    Education
    Holds an MBA from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.
    Tenure
    Joined NMTC in July 2017 as Chief Executive Officer, President, and Director, and has maintained this leadership role while overseeing the merger of NeuroOne, Inc. into NMTC in December 2019.

    Also at NeuroOne Medical Technologies Corp

    CV
    Christopher Volker
    Chief Operating Officer
    MC
    Mark Christianson
    Business Development Director and Medical Sales Liaison
    RM
    Ronald McClurg
    Chief Financial Officer

    About

    David Rosa has built an impressive career in the medical device industry, demonstrating a strong blend of technical, strategic, and operational leadership throughout his journey. His dedication and expertise have seen him traverse several high-level roles in prominent companies, contributing to groundbreaking advancements and capital market successes, including raising $200 million.

    Prior to his current role at NMTC, he led organizations as Chief Executive Officer and President at Sunshine Heart, Inc. (now Nuwellis, Inc.) and was at the helm at Milksmart, Inc., with earlier significant contributions at St. Jude Medical, Inc. and other industry leaders.

    Beyond his executive roles, his career is marked by influential board memberships and a commitment to innovation—holding multiple patents in medical devices—and building robust teams to drive growth and change across sectors.

    His extensive background and leadership acumen have not only shaped the strategic initiatives at NMTC but also inspired a broader industry vision, positioning him as a key figure in advancing healthcare technologies.

    $NMTC Performance Under David Rosa

    Past Roles

    OrganizationRoleDate RangeDetails
    NeuroOne, Inc. CEO and DirectorOctober 2016 - December 2019Merged with NMTC
    Sunshine Heart, Inc. (now Nuwellis, Inc.) CEO and PresidentNovember 2009 - November 2015Publicly-held early-stage medical device company
    Milksmart, Inc. CEO2008 - November 2009Company specialized in medical devices for animals
    St. Jude Medical, Inc. Vice President of Global Marketing2004 - 2008Focused on cardiac surgery and cardiology
    C.R. Bard Inc. Senior RoleN/AInvolved in marketing, product development, and business development
    Boston Scientific Inc. Senior RoleN/AResponsibilities in marketing, product development, and business development

    External Roles

    OrganizationRoleDate Range
    Biotricity Inc. (Nasdaq: BTCY) DirectorN/A
    BioRestorative Therapies, Inc. (Nasdaq: BRTX) DirectorN/A
    Healthcare Triangle, Inc. (Nasdaq: HCTI) DirectorN/A

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary $521,856 Regular payroll disbursement throughout FY 2024N/A
    Severance Benefits in Case of Change in Control $1,565,568 total cash payment Lump sum upon termination due to change in controlCash Payment breakdown: 2.0× base salary ($1,043,712 ) + 2.0× target bonus ($521,856 ). Also includes full vesting of equity awards and 24-month company-paid health insurance.

    Performance Compensation

    Data from  FY 2024

    Non-Equity Incentive Plan Compensation

    Metric [Unit]**Details
    Target Bonus (% of Base Salary)50%, equating to $260,928
    Performance MetricsResearch & development goals, financing goals, commercialization milestones, and corporate objectives
    Achievement Level / Threshold85% achievement of performance targets
    Actual Bonus PaymentApproximately $221,789 (85% of target bonus, i.e., 0.85 × $260,928)
    Evaluation PeriodFiscal Year 2024
    Vesting ScheduleN/A

    Equity-Based Incentive Awards

    Metric [Unit]**Details
    Vesting Schedule (Stock Options)25% vest on November 9, 2024 and the remaining shares vest in equal monthly installments over the following 36 months
    Vesting Schedule (Restricted Stock Units)25% vest on the first, second, third, and fourth anniversaries of February 18, 2024, beginning February 18, 2025
    Grant Date Fair Value (Stock Options)$562,175
    Performance Metrics / TargetsNot provided for the equity awards

    Note: Detailed thresholds, caps, weights, and other specific performance conditions were not provided in the documents.